8-K: MetaVia Presents Promising Obesity and Metabolic Disease Data

MetaVia Inc. announced new late-breaking data for its obesity and metabolic disease portfolio, including positive Phase 1 results for DA-1726 and preclinical combination data for vanoglipel.

Summary

• MetaVia Inc. presented new data at the American Diabetes Associations (ADA) 2026 Scientific Sessions regarding its obesity and metabolic disease pipeline.
• New Phase 1 results for DA-1726, a dual GLP1R/GCGR agonist, showed a 9.1% body weight reduction at Day 54 in the 48 mg cohort, with no evidence of plateau.
• Preclinical data for vanoglipel (DA-1241), a GPR119 agonist, demonstrated synergistic effects when combined with resmetirom for MASH and with metformin for type 2 diabetes.
• The vanoglipel and resmetirom combination showed significant reductions in body weight (23.6%) and improved liver markers in a MASH mouse model.
• The vanoglipel and metformin combination showed enhanced glycemic control (28.7% non-fasting glucose reduction) and body weight reduction (16.3%) in a T2D mouse model.
• These results support the continued development of DA-1726 for obesity and vanoglipel as a versatile combination therapy for MASH and T2D.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with promising clinical and preclinical data supporting the company's pipeline candidates for significant unmet needs in obesity and metabolic diseases.

Positives

• DA-1726 achieved a clinically meaningful 9.1% body weight reduction at Day 54 in the 48 mg cohort, with continued reductions and no plateau observed.
• DA-1726 demonstrated statistically significant reductions in waist circumference (9.8 cm) and BMI (3.4 kg/m) at Day 54.
• DA-1726 was generally well tolerated in the Phase 1 study, with predominantly mild-to-moderate and transient gastrointestinal adverse events and no treatment-related discontinuations or serious adverse events.
• Vanoglipel combined with resmetirom showed synergistic hepatoprotective and weight-loss effects, achieving a 23.6% body weight reduction in a MASH mouse model.
• The combination of vanoglipel and resmetirom led to an 83.5% reduction in ALT levels, indicating significant liver benefit.
• Vanoglipel combined with metformin demonstrated enhanced metabolic and weight effects, including a 16.3% body weight reduction in a T2D mouse model.
• The vanoglipel and metformin combination resulted in significant reductions in non-fasting glucose (28.7%) and fasting glucose (22.7%).
• Preclinical data suggests vanoglipel has potential as a versatile backbone for combination therapies in MASH and type 2 diabetes.

Negatives

• The Phase 1 results for DA-1726 are interim and from a study in obese but otherwise healthy adults, not patients with established metabolic diseases.
• The vanoglipel data is preclinical and derived from mouse models, not human clinical trials.
• Gastrointestinal adverse events, though predominantly mild-to-moderate and transient, were reported with DA-1726.

Risks

• The sufficiency of MetaVia's existing cash on hand to fund operations and the need to raise additional capital.
• Adverse global economic conditions could impact the company's operations and development timelines.
• MetaVia's ability to execute on its commercial strategy and obtain regulatory approval for its product candidates.
• Potential negative interactions between MetaVia's product candidates and other products they may be combined with.
• Risks associated with initiating and completing clinical trials on a timely basis and recruiting subjects.
• The possibility that clinical trial results may not be consistent with preclinical or previous clinical trial results.
• Costs related to the license agreement with Dong-A ST Co. Ltd., including potential litigation or regulatory actions.
• Changes in applicable laws, regulations, or Nasdaq listing rules.

Future Outlook

Results from Phase 1 Part 3 titration studies for DA-1726, designed to assess higher-dose exposure and durability of metabolic response, are expected in the fourth quarter of 2026. The company continues to advance its pipeline for obesity and metabolic diseases.

Management Comments

• "The data highlighted favorable safety, tolerability and clinically meaningful reductions in body weight and waist circumference for DA-1726 at the 48 mg dose level, while the vanoglipel presentations demonstrated synergistic metabolic, liver-related effects and weight loss when combined with current standards of care, supporting potential combination strategies across MASH, T2D and obesity."
• "DA-1726 demonstrated clinically meaningful and progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau, along with consistent reductions in waist circumference and BMI in a once-weekly regimen without titration."
• "Importantly, the data also demonstrates a sustained and progressive metabolic effect through Day 54, supporting continued advancement of higher-dose evaluation in our ongoing Phase 1 Part 3 titration studies designed to assess higher-dose exposure and durability of metabolic response, with results expected in the fourth quarter of 2026."
• "In parallel, preclinical vanoglipel combination data demonstrated synergistic effects across liver and metabolic disease models, including meaningful improvements in hepatic steatosis, liver injury markers, fibrosis-related biomarkers, glycemic control, and body weight."
• "Importantly, when combined with resmetirom, vanoglipels ability to unlock synergistic benefits highlights its potential as a combination strategy for MASH."
• "In addition, when combined with metformin, vanoglipel improved glycemic control and reduced body weight to a greater extent than either monotherapy, further supporting its potential as a therapeutic combination strategy for additional metabolic benefit in T2D."
• "Taken together, these findings further support DA-1726 as a differentiated obesity therapy and vanoglipel as a versatile metabolic backbone for combination approaches in MASH and type 2 diabetes."

Industry Context

StockSavvy.ai notes that the presented data from MetaVia Inc. aligns with the significant industry focus on developing novel therapies for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The dual-agonist approach for DA-1726 and combination strategies for vanoglipel reflect a broader trend in the pharmaceutical sector to achieve more potent and comprehensive therapeutic effects by targeting multiple pathways.

Comparison to Industry Standards

• DA-1726's 9.1% body weight reduction at Day 54 in the 48 mg cohort is competitive with other GLP-1 receptor agonists and dual agonists in development, though direct comparisons require longer-term data and head-to-head trials.
• The preclinical synergistic effects of vanoglipel with resmetirom in MASH models are promising, as combination therapies are increasingly seen as the future for treating complex liver diseases like MASH, where single agents have shown limited efficacy.
• The combination of vanoglipel with metformin showing enhanced glycemic control and weight loss in preclinical models is consistent with the strategy of combining agents with different mechanisms to achieve superior outcomes, a common approach in type 2 diabetes management.

Stakeholder Impact

• Shareholders may see increased confidence in the company's pipeline and future prospects due to the positive data presentations.
• Patients with obesity, MASH, and type 2 diabetes may benefit from the potential development of more effective treatment options.
• The scientific community will gain insights into the therapeutic potential of dual agonists and combination therapies in cardiometabolic diseases.

Next Steps

• Continue development of DA-1726 for obesity.
• Advance higher-dose evaluation of DA-1726 in Phase 1 Part 3 titration studies.
• Explore combination strategies for vanoglipel in MASH and type 2 diabetes.
• Await results from Phase 1 Part 3 titration studies for DA-1726, expected in Q4 2026.

Key Dates

Recommendation

The presented data is promising and supports the continued development of MetaVia's pipeline. However, the DA-1726 results are interim Phase 1 data in healthy adults, and the vanoglipel data is preclinical. Further clinical validation in target patient populations is required before a stronger recommendation can be made. The company also faces risks related to funding and regulatory approvals.

Keywords

obesity, metabolic disease, DA-1726, vanoglipel, MASH, type 2 diabetes, GLP1R agonist, GPR119 agonist